Clinical Trials Directory
This study has two parts. In the first part, called Phase 1a, doctors will test different amounts of a medicine called PHN-012 to find the safest dose. In the second part, called Phase 1b, doctors will see how well PHN-012 works against cancer. The medicine will be given through an IV, which means it goes into a vein. You will get the medicine every 21 days until your cancer gets worse or you have to stop because of bad side effects.
We are doing this study to find out if an experimental drug called PHTS001 (the study drug) is a safe and effective option for people who have advanced relapsed or refractory solid tumors.
We are doing this study to find out if the combination of two hormonal drugs, giredestrant and fulvestrant, are a safe and effective option if they are given with the study doctor's choice of a class of medicines called CDK4/6 inhibitors to people who have ER-positive, HER2-negative breast cancer that is resistant to standard treatments.
We are doing this study to find out if the combination of an experimental drug called ONC201 (the study drug) with paxalisib is an effective option for patients with a diffuse midline glioma (DMG). We also want to see how much of these drugs are absorbed by tumor tissue in patients with brain tumors.
We are doing this study to find out if an experimental drug called ADI-PEG 20 (the study drug) combined with two types of FDA-approved chemotherapies (gemcitabine and docetaxel) is a safe and effective option for people who have leiomyosarcoma.
We are doing this study to find out if adding azithromycin to the routine single antibiotic preventative therapy can lower the risk of developing infections after a cesarean delivery.
We are doing this study to learn more about how 2 different classes of diabetes medications help lower the risk of heart disease. The types of diabetes medications that have been shown to reduce the risk of new or worsening heart disease are SGLT2 inhibitors and GLP-1 receptor agonists. We don't know which of these drugs might be preferable to reduce heart disease risk for diabetes patients, and we hope this study can help us find out which drug(s) may be the most appropriate for most patients.